{"name":"Eszopiclone","slug":"eszopiclone","kind":"substance","abbreviations":[],"systematic":null,"aliases":["Lunesta","(S)-Zopiclone","Estorra","Esopiclone","(+)-Zopiclone","Eszopiclon","Eszopiclone civ","Sep-190","eszopiclona","Gsk-1755165"],"brands":[],"scraped":true,"has_structure":true,"cid":969472,"classes":[],"families":[{"name":"cyclopyrrolone","href":"/substituted/cyclopyrrolone"}],"physical":[{"label":"Molecular mass","value":"388.80 g/mol","copyable":false},{"label":"Appearance","value":"White to light-yellow crystalline solid","copyable":false},{"label":"Melting point","value":"202-203","copyable":false},{"label":"Boiling point","value":"487.2","copyable":false},{"label":"Solubility","value":"soluble in water","copyable":false},{"label":"Predicted LogP","value":"0.5","copyable":false}],"identifiers":[{"label":"Molecular formula","value":"C<sub>17</sub>H<sub>17</sub>ClN<sub>6</sub>O<sub>3</sub>","copyable":true},{"label":"IUPAC name","value":"[(7S)-6-(5-chloro-2-pyridinyl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate","copyable":true},{"label":"SMILES","value":"CN1CCN(CC1)C(=O)O[C@H]2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl","copyable":true},{"label":"InChI","value":"InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1","copyable":true},{"label":"InChIKey","value":"GBBSUAFBMRNDJC-INIZCTEOSA-N","copyable":true},{"label":"CAS number","value":"138729-47-2","copyable":true},{"label":"UNII","value":"UZX80K71OE","copyable":true},{"label":"PubChem CID","value":"969472","copyable":true}],"pharmacokinetics":[{"label":"Elimination half-life","value":"6 hours","copyable":false},{"label":"Metabolism","value":"Liver oxidation and demethylation (CYP3A4 and CYP2E1-mediated)","copyable":false},{"label":"Excretion","value":"Kidney","copyable":false},{"label":"Routes of administration","value":"By mouth","copyable":false}],"toxicity":[],"dosing":{"provider":"DBI-IGS (archived by anodyne.wiki)","routes":[{"method":"Sublingual","tiers":{"Common":{"lower":6.8,"upper":8.8,"unit":"mg","entries":5,"percentage":22.7},"Extreme":{"lower":14.7,"upper":14.7,"unit":"mg","entries":3,"percentage":13.6},"Heavy":{"lower":10.0,"upper":14.7,"unit":"mg","entries":1,"percentage":4.5},"Light":{"lower":6.8,"upper":6.8,"unit":"mg","entries":6,"percentage":27.3},"Strong":{"lower":8.8,"upper":10.0,"unit":"mg","entries":7,"percentage":31.8}}},{"method":"Oral","tiers":{"Common":{"lower":13.2,"upper":20.0,"unit":"mg","entries":5,"percentage":23.8},"Extreme":{"lower":30.0,"upper":30.0,"unit":"mg","entries":0,"percentage":0.0},"Heavy":{"lower":22.5,"upper":30.0,"unit":"mg","entries":5,"percentage":23.8},"Light":{"lower":13.2,"upper":13.2,"unit":"mg","entries":10,"percentage":47.6},"Strong":{"lower":20.0,"upper":22.5,"unit":"mg","entries":1,"percentage":4.8}}}]},"salts":[],"esters":[],"chirality":"absolute","stereo_type":null,"optical_activity":"( + )","stereoisomers":[],"lipinski":{"passes":true,"violations":0},"reagents":[],"atc":[{"code":"N","description":"Nervous system"},{"code":"N05","description":"Psycholeptics"},{"code":"N05C","description":"Hypnotics and sedatives"},{"code":"N05CF","description":"Benzodiazepine related drugs"},{"code":"N05CF04","description":"Eszopiclone"}],"mesh":[{"name":"Hypnotics and Sedatives","id":"M0010885"}],"actives":[],"prodrugs":[],"codrug":false,"interactions":[{"target":"CYP3A4","mechanisms":["metabolism","inhibition","induction"],"partners":216,"contraindicated":0},{"target":"GABRA1","mechanisms":["shared target"],"partners":29,"contraindicated":0},{"target":"GABRA2","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRA3","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRA4","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRA5","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRA6","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRB1","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRB2","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRB3","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRD","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRE","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRG1","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRG2","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRG3","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRP","mechanisms":["shared target"],"partners":27,"contraindicated":0},{"target":"GABRQ","mechanisms":["shared target"],"partners":27,"contraindicated":0}],"mechanism":"The exact mechanism of action of eszopiclone is unknown at this time but is thought to occur via binding with the GABA receptor complexes at binding sites located near benzodiazepine receptors, possibly explaining its hypnotic and sedative effects. It has particular affinity for GABA-A (or GABAA) receptor subunits 1, 3 and 5. Eszopiclone increases GABA-A channel currents significantly. GABA-A channels are major inhibitory channels that cause CNS depression when their receptors are activated.","side_effects":null,"effects":null,"usernotes":[],"erowid":[],"reddit":[],"legal":[{"jurisdiction":"Brazil","status":"B1","act":null,"refs":[3]},{"jurisdiction":"United States","status":"Schedule IV","act":"Controlled Substances Act","refs":[4]}],"members":[],"part_of":[],"links":[{"source":"Wikipedia","url":"https://en.wikipedia.org/wiki/Eszopiclone"},{"source":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/969472"},{"source":"Wikidata","url":"https://www.wikidata.org/wiki/Q413184"},{"source":"DrugBank","url":"https://go.drugbank.com/drugs/DB00402"},{"source":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1522"},{"source":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI%3A53760"},{"source":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=138729-47-2"},{"source":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0014546"},{"source":"KEGG","url":"https://www.kegg.jp/entry/D02624"},{"source":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID8046086"},{"source":"Effect Index","url":"https://www.effectindex.com/search?q=Eszopiclone"},{"source":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/UZX80K71OE"}],"references":["National Center for Biotechnology Information. PubChem Compound Summary for CID 969472, Eszopiclone. Accessed November 21, 2026. <a href=https://pubchem.ncbi.nlm.nih.gov/compound/969472>https://pubchem.ncbi.nlm.nih.gov/compound/969472</a>","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Eszopiclone. UNII: UZX80K71OE. Global Substance Registration System. Accessed November 21, 2026. <a href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/UZX80K71OE>https://gsrs.ncats.nih.gov/ginas/app/beta/substances/UZX80K71OE</a>","RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. <a href='https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992'>https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992</a>","Lunesta- eszopiclone tablet, coated. DailyMed. 24 May 2023. <a href='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd047b2b-05a6-4d99-95cb-955f14bf329f'>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd047b2b-05a6-4d99-95cb-955f14bf329f</a>"],"sources":[{"source":"dosing","status":"ok","fetched_at":"2026-11-20 18:59:57","note":null},{"source":"drugspro","status":"missing","fetched_at":"2026-11-20 18:59:53","note":"no DrugsPRO reagent data"},{"source":"erowid","status":"missing","fetched_at":"2026-11-20 18:59:53","note":"no Erowid substance of that name"},{"source":"gsrs","status":"ok","fetched_at":"2026-11-20 18:59:53","note":null},{"source":"hmdb","status":"missing","fetched_at":"2026-11-20 18:59:53","note":"hmdb.ca refused automated access to HMDB0014546"},{"source":"kegg","status":"ok","fetched_at":"2026-11-20 18:59:55","note":null},{"source":"pubchem","status":"ok","fetched_at":"2026-11-20 18:59:53","note":null},{"source":"reddit","status":"missing","fetched_at":"2026-11-20 18:59:53","note":"no r/tripreports posts mention it"},{"source":"sider","status":"missing","fetched_at":"2026-11-20 18:59:53","note":"not in SIDER"},{"source":"structure","status":"ok","fetched_at":"2026-11-20 18:59:53","note":null},{"source":"wikipedia","status":"ok","fetched_at":"2026-11-20 18:59:53","note":null}],"description":"Eszopiclone is a  substance."}